Although gemfibrozil was discontinued soon after, he presented with rhabdomyolysis with acute kidney injury 1 month later. Rhabdoymyolysis is a rare complication and may cause acute renal failure, which may be fatal. Do not start, stop, or change the dosage of any medicine before checking with them first.Selected from data included with permission and copyrighted by First Databank, Inc.
This site needs JavaScript to work properly. He needed hemodialysis due to refractory hyperkalemia, metabolic acidosis, and fluid overload. A higher risk of serious adverse events results from combining these drugs, and systems to improve adherence to guidelines may improve the safety of treating dyslipidemic patients. 2006 Nov-Dec;12(9):745-51. doi: 10.18553/jmcp.2006.12.9.745.Expert Rev Cardiovasc Ther. 2011 Feb;9(2):131-45. doi: 10.1586/erc.10.179.Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, Di Biase M, Brunetti ND.Vasc Health Risk Manag. Name must be less than 100 characters Table 2.
This is the first case reporting rhabdomyolysis with renal impairment presenting 4 weeks after discontinuing fibrate after muscle symptoms.
13 As of April 2018, the Food and Drug Administration adverse event reporting system (FAERS) database contained 280 reports of tendon rupture associated with simvastatin therapy, and one case of tendon rupture associated with gemfibrozil, since 1994. Triglycerides may be reduced by as much as 74 % in some patients. Conclusion: Combination therapy with simvastatin and gemfibrozil often did not meet ATP III standards. eCollection 2017.Ko Y, Malone DC, Skrepnek GH, Armstrong EP, Murphy JE, Abarca J, Rehfeld RA, Reel SJ, Woosley RL.Drug Saf.
Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.Severe. WebMD provides information about interactions between Gemfibrozil (Bulk) and gemfibrozil-simvastatin.
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are associated with myopathy, myalgias, myositis, and rhabdomyolysis. We believe that the summative and synergistic properties of statin … Clin Pharmacol Ther 2000 Aug;68(2):122-9. COVID-19 is an emerging, rapidly evolving situation. These medicines may interact and cause very harmful effects and are usually not taken together. 2008;31(6):525-36. doi: 10.2165/00002018-200831060-00007. In such cases, alternative therapies should be considered. One death secondary to rhabdomyolysis occurred in a patient whose care did not meet ATP III guidelines. Rhabdomyolysis … Gemfibrozil is a lipid-modifying agent that belongs to the fibric acid derivative class. Clipboard, Search History, and several other advanced features are temporarily unavailable. 7 22. 1999 Jul;138(1 Pt 1):151-5. doi: 10.1016/s0002-8703(99)70261-9.J Manag Care Pharm.
A pharmacovigilance study from France reported 30 possible cases of spontaneous tendon rupture attributed to the use of simvastatin. Unable to load your delegates due to an error Elsevier Science Although monotherapy with cerivastatin is well tolerated and has a low frequency of adverse events, the combination with nicotinic acid (i.e., niacin) or a fibric-acid derivative (i.e., gemfibrozil, fenofibrate) may result in severe skeletal muscle toxicity and rhabdomyolysis. 21 There is also evidence that statins are metabolised by the glucuronidation pathway and that MRP2 inhibitors such as gemfibrozil can increase the risk of rhabdomyolysis 10-fold.
Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Gemfibrozil is a drug which is extensively metabolized by the liver and excreted mainly by the kidneys with an elimination half-life of 1.5 hours .
Co-prescribed drugs most commonly causing rhabdomyolysis with statins 1 9.